Project Grant R01FD008187
Award Date
9/15/24
Completion Date
7/31/29
Dollars Obligated
$882K
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant awarded by the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $1,300,000 to the Sloan-Kettering Institute for Cancer Research to conduct a Phase 2A/2B clinical trial evaluating the use of the interferon-gamma neutralizing monoclonal antibody emapalumab as a prophase therapy for pediatric patients with newly diagnosed acquired aplastic anemia. The trial aims to assess if this prophase can help identify patients most likely to respond favorably to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $612,975.00 to the University of Pittsburgh to conduct research on "Targeting Monocyte Allorecognition to Achieve Allograft Acceptance". The goal is to develop a model for inducing long-term organ transplant acceptance by combining T-cell costimulation blockade with inhibition of monocyte allorecognition via CD47. The research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
The federal Project Grant award of $4,029,612 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "INFLUENCE TRIAL: IMPROVING EVENT-FREE SURVIVAL BY OPTIMIZING FLUDARABINE EXPOSURE DURING LYMPHODEPLETION FOR CAR T CELL THERAPY" at the Sloan-Kettering Institute for Cancer Research in New York. This grant aims to optimize fludarabine exposure during lymphodepletion to improve event-free survival for patients receiving CAR T-cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $185,831 to the University of Pittsburgh for a 2-year research project focused on discovering and developing allosteric inhibitors of the Src-family kinases HCK and FGR as potential treatments for acute myeloid leukemia (AML). The research aims to: 1) Synthesize and test analogs of existing allosteric modulators for the AML-associated kinase HCK, and 2) Identify additional scaffolds for...
This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on the role of CD91-mediated signaling in cancer immunosurveillance. The research aims to develop a new mouse model to test the importance of CD91 signaling in response to tumor-derived heat shock proteins (HSPs) for priming T cell responses against nascent, emerging tumors. The goal is to better understand the mechanisms by...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $231,131 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Duquesne University of the Holy Spirit to develop injectable 3D-clustered human fibroblastic reticular cells (clFRCs) for expanding regulatory T cells (Tregs) to manage allograft transplant rejection. The 2-year project, running from June 2025 to May 2027, aims to optimize the clFRC prototype to generate Tregs in vitro and characterize the...
This federal Project Grant award of $613,793.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research on immunosuppressive factors contributing to immunotherapy resistance in endometrial cancer with deficient mismatch repair. The primary awardee, Magee-Womens Research Institute and Foundation, will be responsible for the overall project, which involves extensive immune monitoring and profiling of tumor and blood samples from a clinical...
This Project Grant award of $584,872.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant supports research to investigate the underlying molecular mechanisms of how mutations in RNA splicing factor genes induce genomic instability in myelodysplastic syndromes (MDS), and to evaluate the therapeutic potential of PARP inhibitors in preclinical MDS models. The project...